CCL2 Protein

<!-- Protein Page -->
<div class="infobox infobox-protein">
<h3>CCL2 Protein</h3>
<div class="infobox-row"><strong>Protein Name:</strong> C-C Motif Chemokine Ligand 2 (MCP-1)</div>
<div class="infobox-row"><strong>Gene:</strong> CCL2</div> [@gu2015]
<div class="infobox-row"><strong>UniProt ID:</strong> P13500</div> [@kim2019]
<div class="infobox-row"><strong>PDB Structure IDs:</strong> 1DOL, 1O7N, 5NJ8</div> [@chandra2020]
<div class="infobox-row"><strong>Molecular Weight:</strong> ~9.9 kDa (monomer), ~18 kDa (dimer)</div> [@szpakowska2012]
<div class="infobox-row"><strong>Subcellular Localization:</strong> Secreted (extracellular)</div>
<div class="infobox-row"><strong>Protein Family:</strong> CC chemokine family</div>
<div class="infobox-row"><strong>Brain Expression:</strong> Neurons, astrocytes, microglia, endothelial cells</div>
</div>

CCL2 (Chemokine C-C Motif Ligand 2)

Introduction

Ccl2 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

...

<!-- Protein Page -->
<div class="infobox infobox-protein">
<h3>CCL2 Protein</h3>
<div class="infobox-row"><strong>Protein Name:</strong> C-C Motif Chemokine Ligand 2 (MCP-1)</div>
<div class="infobox-row"><strong>Gene:</strong> CCL2</div> [@gu2015]
<div class="infobox-row"><strong>UniProt ID:</strong> P13500</div> [@kim2019]
<div class="infobox-row"><strong>PDB Structure IDs:</strong> 1DOL, 1O7N, 5NJ8</div> [@chandra2020]
<div class="infobox-row"><strong>Molecular Weight:</strong> ~9.9 kDa (monomer), ~18 kDa (dimer)</div> [@szpakowska2012]
<div class="infobox-row"><strong>Subcellular Localization:</strong> Secreted (extracellular)</div>
<div class="infobox-row"><strong>Protein Family:</strong> CC chemokine family</div>
<div class="infobox-row"><strong>Brain Expression:</strong> Neurons, astrocytes, microglia, endothelial cells</div>
</div>

CCL2 (Chemokine C-C Motif Ligand 2)

Introduction

Ccl2 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

C-C Motif Chemokine Ligand 2 (CCL2), also known as Monocyte Chemoattractant Protein-1 (MCP-1), is a small secreted chemokine that plays a central role in recruiting monocytes, [microglia](/cell-types/microglia-neuroinflammation), and other immune cells to sites of inflammation. In the central nervous system, CCL2 is produced by [neurons](/entities/neurons), astrocytes, microglia, and endothelial cells, creating a chemotactic gradient that guides immune cells during infection, injury, and disease.

CCL2 has emerged as a critical player in neurodegenerative diseases, with elevated levels documented in [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), multiple sclerosis, and other neurological conditions. The protein represents a key link between peripheral immune activation and central nervous system inflammation, making it an important therapeutic target and potential biomarker for neuroinflammatory disorders.

Molecular Biology

Gene Structure and Regulation

The CCL2 gene is located on chromosome 17q12 in humans and encodes a 99-amino acid protein that is secreted following proteolytic processing. Key regulatory features include:

• Promoter elements: Contains binding sites for [NF-κB](/entities/nf-kb), AP-1, and other transcription factors responsive to inflammatory stimuli
• Tissue-specific expression: Constitutively expressed at low levels in many tissues; dramatically upregulated by pro-inflammatory cytokines
• Alternative splicing: Produces multiple splice variants with potentially distinct functions

Protein Structure

CCL2 belongs to the CC chemokine family, characterized by adjacent cysteine residues near the N-terminus:

• N-terminal region: Contains the receptor-binding site; critical for receptor activation
• Core domain: Consists of a beta-sheet with three anti-parallel strands
• C-terminal helix: Contributes to glycosaminoglycan binding
• Disulfide bonds: Two conserved disulfide bonds (Cys-Cys) stabilize the structure

The three-dimensional structure reveals a monomer-dimer equilibrium, with the dimer form potentially serving as a storage or regulation mechanism.

Receptor Binding

CCL2 signals primarily through the CCR2 receptor (C-C chemokine receptor type 2), a G protein-coupled receptor (GPCR) expressed on monocytes, microglia, and other immune cells. Additional receptors include:

• CCR4: Lower affinity binding
• D6: Decoy receptor that scavenges CCL2
• ACKR2: Acts as a scavenger receptor

Normal Physiological Functions

Immune Cell Recruitment

CCL2's primary function is to attract immune cells to sites requiring surveillance or response:

Monocyte recruitment: The most well-characterized function; CCL2 is the principal chemoattractant for monocytes in inflammation

Microglial attraction: Directs microglia to areas of neuronal injury or protein aggregation

T cell recruitment: Attracts memory and effector T cells, particularly the Th2 subset

NK cell recruitment: Participates in natural killer cell trafficking

Central Nervous System Functions

In the healthy brain, CCL2 performs important homeostatic functions:

• Immune surveillance: Maintains baseline microglial monitoring
• Development: May play roles in neural development and plasticity
• Repair: Promotes cleanup of cellular debris following injury

Role in Neurodegenerative Diseases

Alzheimer's Disease

CCL2 is profoundly implicated in Alzheimer's disease pathogenesis through multiple mechanisms:

Amyloid Plaque Association

• CCL2 is highly upregulated around [amyloid-beta](/proteins/amyloid-beta) (Aβ) plaques
• [Astrocytes](/entities/astrocytes) and microglia surrounding plaques produce CCL2
• Creates a chronic chemoattractant gradient that maintains microglial activation

Microglial Recruitment

• CCL2 recruits microglia to sites of Aβ deposition
• Initial recruitment may be protective (phagocytic clearance)
• Chronic exposure leads to dysregulated, inflammatory microglia

Neuroinflammation

• Elevated CCL2 in AD brain tissue and cerebrospinal fluid
• Levels correlate with disease severity
• Drives persistent neuroinflammation that contributes to neuronal dysfunction

[Blood-Brain Barrier](/entities/blood-brain-barrier) Permeability

• CCL2 disrupts blood-brain barrier integrity
• Enables peripheral monocyte entry into the brain
• Links peripheral inflammation to central pathology

Parkinson's Disease

In Parkinson's disease, CCL2 contributes to dopaminergic neuron loss:

Substantia Nigra Activation

• CCL2 expression is elevated in the substantia nigra of PD patients
• Attracts microglia to the region of dopaminergic neuron loss
• Creates a self-perpetuating inflammatory loop

CSF and Blood Biomarkers

• Elevated CCL2 in cerebrospinal fluid of PD patients
• Peripheral CCL2 levels correlate with disease progression
• Potential biomarker for disease monitoring

Mechanism of Neurotoxicity

• Chronic CCL2 signaling promotes production of neurotoxic factors
• TNF-α, IL-1β, and nitric oxide released by CCL2-activated microglia
• Contributes to progressive dopaminergic neuron degeneration

Multiple Sclerosis

CCL2 plays a critical role in the autoimmune demyelination characteristic of MS:

Leukocyte Recruitment

• Essential for monocyte and T cell recruitment across the blood-brain barrier
• Upregulated on endothelial cells in active lesions
• Enables immune cell infiltration into CNS parenchyma

Disease Progression

• CCL2 levels in CSF correlate with disease activity
• Anti-CCL2 strategies reduce disease severity in animal models
• Blockade of CCL2-CCR2 signaling ameliorates experimental autoimmune encephalomyelitis (EAE)

Amyotrophic Lateral Sclerosis

In ALS, CCL2 contributes to the inflammatory environment surrounding motor neurons:

• Elevated CCL2 in spinal cord and CSF of ALS patients
• Attracts microglia and monocytes to sites of motor neuron degeneration
• May exacerbate inflammatory-mediated motor neuron death

Stroke and Ischemic Injury

Following cerebral ischemia:

• Rapid upregulation of CCL2 in ischemic tissue
• Mediates post-ischemic inflammation
• Contributes to secondary neuronal injury
• CCL2 blockade reduces infarct size in experimental models

Therapeutic Implications

Biomarker Potential

CCL2 has significant potential as a biomarker:

• CSF CCL2: Elevated in AD, PD, MS, and stroke
• Blood CCL2: Peripheral measurements may reflect CNS inflammation
• Longitudinal tracking: Levels may correlate with disease progression

Therapeutic Targeting

The CCL2-CCR2 axis is a major therapeutic target:

CCR2 Antagonists

• Multiple CCR2 antagonists in clinical development
• Target: Block monocyte/microglia recruitment to sites of inflammation
• Conditions: Autoimmune diseases, inflammatory disorders, potentially neurodegeneration

Anti-CCL2 Antibodies

• Monoclonal antibodies neutralize CCL2 activity
• Preclinical studies show promise in neuroinflammatory models
• Challenges: Blood-brain barrier penetration

Small Molecule Inhibitors

• CCR2 small molecule antagonists
• May achieve better CNS penetration than biologics
• Early clinical trials for various indications

Natural Compounds

• Certain flavonoids and polyphenols reduce CCL2 expression
• Curcumin, resveratrol show anti-CCL2 effects in vitro
• Complementary approach to conventional therapeutics

Research Challenges

Therapeutic modulation of CCL2 faces several challenges:

• Complexity: CCL2 has both protective and harmful functions
• Redundancy: Other chemokines can compensate for CCL2 blockade
• BBB penetration: Many therapeutics cannot reach CNS targets
• Timing: Benefits may depend on disease stage

Genetics

Polymorphisms

CCL2 gene variants affect disease risk:

• CCL2-2518 A/G polymorphism: GG genotype associated with increased CCL2 expression and higher AD risk
• Promoter variants: Affect transcription factor binding and expression levels
• Disease associations: Certain variants linked to MS, RA, and cardiovascular disease

Expression Regulation

CCL2 expression is tightly regulated at multiple levels:

• Transcriptional: NF-κB, AP-1, IRF-1 respond to inflammatory signals
• Post-transcriptional: mRNA stability elements affect half-life
• Epigenetic: [DNA methylation](/entities/dna-methylation) and [histone modifications](/entities/histone-modifications) influence expression

Cross-links

• [CCL2 Gene](/genes/CCL2)
• [Mechanisms/Neuroinflammation](/content/mechanisms)
• [Mechanisms/Microglial Activation](/entities/microglia)
• [Cell Types/Microglia](/entities/microglia)
• [Cell Types/Astrocytes](/entities/astrocytes)
• [diseases/alzheimers](/content/diseases)
• [Diseases/Parkinson's Disease](/proteins/parkin)
• [diseases/multiple-sclerosis](/content/diseases)
• [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
• [Diseases/Stroke](/diseases/stroke)

See Also

• [CCR2 Gene](/genes/CCR2) - Receptor for CCL2
• [CCL2 Protein](/proteins/CCL2-Protein) - This protein
• [Neuroinflammation](/mechanisms/neuroinflammation) - Inflammatory mechanisms
• [Chemokine Signaling](/mechanisms/chemokine-signaling) - Signaling pathways

Background

The study of Ccl2 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/) - Biomedical literature
• [Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/) - Research data
• [Allen Brain Atlas](https://brain-map.org/) - Brain gene expression data

References

[Deshmane SL, et al, (2009) (2009)](https://pubmed.ncbi.nlm.nih.gov/19441883/))

[Jing GB, et al, (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/31351772/))

[Conductier G, et al, (2010) (2010)](https://pubmed.ncbi.nlm.nih.gov/20681017/))

[Yao Y, et al, (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/31394268/))

[Gu H, et al, (2015) (2015)](https://pubmed.ncbi.nlm.nih.gov/25620279/))

[Kim MS, et al, (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/30947183/))

[Chandra S, et al, (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32879517/))

[Szpakowska M, et al, (2012) (2012)](https://pubmed.ncbi.nlm.nih.gov/22940636/))